Autres langues Amphastar Pharmaceuticals, Inc.

Actions

AMPH

US03209R1032

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 06/05/2024			Varia. 5j.	Varia. 1 janv.
42,68 ^USD	+0,52 %		+1,57 %	-30,99 %

30/04	La FTC conteste les listes de brevets "inutiles" pour Ozempic, Victoza et d'autres médicaments	MT
30/04	Les principaux événements de la mi-journée : Les actions d'Eli Lilly et de HSBC bénéficient d'un coup de pouce après la publication des résultats ; BBVA envisage une fusion avec Sabadell ; la FTC conteste 300 listes de brevets "inutiles".	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing	08/03
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023	29/02
Sector Update: Health Care Stocks Advance Premarket Thursday	29/02
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise	29/02
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023	28/02
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Amphastar: Q4 Earnings Snapshot	28/02
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91	28/02
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M	28/02
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024	21/02
High-dose opioid reversal spray no better than lower dose in field, US study finds	08/02
Amphastar Pharmaceuticals Insider Sold Shares Worth $7,171,768, According to a Recent SEC Filing	11/01
Amphastar Pharmaceuticals Insider Sold Shares Worth $12,798,708, According to a Recent SEC Filing	11/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Amphastar Pharmaceuticals, Inc.

Actions

AMPH

US03209R1032

Autres langues

Filtres